X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207480
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204801
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217399
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206720
https://www.business-standard.com/article/news-cm/iol-chemicals-secures-patent-for-invention-related-to-preparation-of-sartan-drugs-122112400926_1.html
https://www.business-standard.com/article/companies/macleods-pharmaceuticals-recalls-products-in-us-for-manufacturing-issues-122031300189_1.html
http://www.koreabiomed.com/news/articleView.html?idxno=12631
https://www.otsuka.co.jp/en/company/newsreleases/2021/20210927_2.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-2-2021-1622637119.pdf
https://www.tga.gov.au/alert/shortage-olmesartan-and-prazosin-tablets#:~:text=Olmesartan%20and%20prazosin%20tablets%20are,Substitution%20Notices%20for%20each%20medicine.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208659
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-12-2020-1581485052.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207135
https://www.raps.org/news-and-articles/news-articles/2019/5/fda-483s-pile-up-in-crackdown-on-sartan-manufactur
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211049
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209281
https://www.edqm.eu/en/news/update-edqm-review-cep-applications-sartan-substances-4-february-2019
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-23-2019-1548227584.pdf
https://www.accessdata.fda.gov/scripts/ires/index.cfm?action=print.getPrintData&ts=11122018102457
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209010
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-5-2018-1544180983.pdf
https://www.ema.europa.eu/documents/press-release/eu-authorities-take-further-action-ongoing-review-sartans_en.pdf
https://www.pharmacompass.com/pdf/news/Health-Canada-finds-Zhejiang-Huahai-Pharmaceuticals-site-non-compliant-with-GMP-1538639316.pdf
https://www.raps.org/news-and-articles/news-articles/2018/9/eu-us-ban-manufacturer-use-of-valsartan-from-chin?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%2028%20September
https://www.raps.org/news-and-articles/news-articles/2018/9/ema-extends-valsartan-review-to-include-four-more?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%2021%20September
https://www.pharmacompass.com/pdf/news/EMA-review-of-impurities-in-sartan-medicines-1538045187.pdf
http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2018/09/WC500255730.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209600
https://www.pharmacompass.com/pdf/news/List-of-New-Paragraph-IV-Certifications-as-of-Aug-21-2018-1534919998.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208130
https://www.tga.gov.au/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines
https://www.fiercepharma.com/pharma/daiichi-sankyo-makes-another-big-whack-at-u-s-sales-operation-280-to-go
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207435
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209042
http://www.fiercepharma.com/legal/fiscally-challenged-daiichi-sankyo-offers-300-million-to-settle-2-300-benicar-lawsuits
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207073
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207807
http://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/jubilant-gets-usfda-nod-for-generic-hypertension-drug/articleshow/58714211.cms
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207450
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206906
http://www.business-standard.com/article/companies/lupin-gets-usfda-nod-to-sell-generic-hypertension-drug-in-us-117042800784_1.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204233
http://economictimes.indiatimes.com/news/industry/healthcare/biotech/pharmaceuticals/alembic-pharma-gets-usfda-nod-for-anti-hypertension-drugs/articleshow/58357915.cms
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204798
Market Place
Share 
